

**Announcement  
2 June 2014****Coloplast – transactions in connection with share buy-back programme**

As mentioned in Announcement No. 2/2014 Coloplast has initiated the first part of the share buy-back programme totalling up to DKK 1bn. This part of the programme of DKK500m is expected to take place from 3 March, 2014 to 31 August, 2014 at the latest.

The following transactions have been executed during the period 26 May – 28 May 2014:

<b>Date</b>	<b>Number of shares</b>	<b>Buying price</b>	<b>Amount DKK</b>
<b>26 May 2014</b>	<b>30,000</b>	<b>470.3000</b>	<b>14,109,000</b>
<b>27 May 2014</b>	<b>30,000</b>	<b>467.3000</b>	<b>14,019,000</b>
<b>28 May 2014</b>	<b>30,000</b>	<b>472.0000</b>	<b>14,160,000</b>
Accumulated until now under the programme	<b>805,000</b>	<b>449.6065</b>	<b>361,933,200</b>

Henceforth, Coloplast owns 9,271,137 own B shares of DKK 1 equal to 4.21% of the company's total share capital.

The second part of the programme, of also DKK 500m, is expected to take place from 1 October, 2014 to 30 September, 2015.

## For further information, please contact

### Investors and analysts

Lene Skole  
Executive Vice President, CFO  
Tel. +45 4911 1700

Ian S.E. Christensen  
Vice President, Investor Relations  
Tel. +45 4911 1800/+45 4911 1301  
Email: dkisec@coloplast.com

Nick Fridberg  
Sr. Investor Relations Manager  
Tel. +45 4911 1800/+45 4911 1456  
Email: dknf@coloplast.com

### Press and the media

Simon Mehl Augustesen  
Media Relations Manager  
Tel. +45 4911 3488  
Email: dksia@coloplast.com

This announcement is available in a Danish and an English-language version.  
In the event of discrepancies, the Danish version shall prevail.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2014-06 All rights reserved Coloplast A/S, 3050 Humlebæk, Denmark.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.

Our business includes Ostomy Care, Urology Care, Continence Care and Wound and Skin Care. We operate globally and employ more than 8,500 people.